Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2009.02.030
DC FieldValue
dc.titlePaclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme
dc.contributor.authorOng, B.Y.S.
dc.contributor.authorRanganath, S.H.
dc.contributor.authorLee, L.Y.
dc.contributor.authorLu, F.
dc.contributor.authorLee, H.-S.
dc.contributor.authorSahinidis, N.V.
dc.contributor.authorWang, C.-H.
dc.date.accessioned2014-10-09T06:56:58Z
dc.date.available2014-10-09T06:56:58Z
dc.date.issued2009-06
dc.identifier.citationOng, B.Y.S., Ranganath, S.H., Lee, L.Y., Lu, F., Lee, H.-S., Sahinidis, N.V., Wang, C.-H. (2009-06). Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 30 (18) : 3189-3196. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2009.02.030
dc.identifier.issn01429612
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/89715
dc.description.abstractPaclitaxel loaded biodegradable poly-(dl-lactic-co-glycolic) acid (PLGA) foams with microporous matrix were fabricated by a novel pressure quenching approach to provide a sustained paclitaxel release. The foams with micropores provided increased surface area to volume ratio and were also implantable for post-surgical chemotherapy applications. The two formulations 5% (w/w) paclitaxel loaded PLGA 85:15 foam (F1) and 10% (w/w) paclitaxel loaded PLGA 50:50 foam (F2), were evaluated in vitro and in vivo. Both the foams were found to provide a paclitaxel release beyond a month in vitro with a near zero-order kinetics and with minimum burst release. Furthermore, apoptosis of C6 glioma cells in vitro demonstrated the benefits of sustained paclitaxel release by the foams in comparison to acute Taxol® exposure. Both the foams exhibited continuous paclitaxel release in an in vivo (subcutaneous) environment up to a month which correlated well with the in vitro release profiles. Bio-distribution results in the rat brain showed paclitaxel penetration at therapeutic levels up to 3 mm into the tissue from the site of foam implantation. Hence these foams could be employed as potential implants for post-surgical chemotherapy against malignant glioma. © 2009 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2009.02.030
dc.sourceScopus
dc.subjectFoams
dc.subjectGlioma
dc.subjectIn vivo bio-distribution
dc.subjectPaclitaxel
dc.subjectPLGA
dc.subjectSustained release
dc.typeArticle
dc.contributor.departmentCHEMICAL & BIOMOLECULAR ENGINEERING
dc.description.doi10.1016/j.biomaterials.2009.02.030
dc.description.sourcetitleBiomaterials
dc.description.volume30
dc.description.issue18
dc.description.page3189-3196
dc.description.codenBIMAD
dc.identifier.isiut000266148200009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

95
checked on Sep 17, 2019

WEB OF SCIENCETM
Citations

89
checked on Sep 17, 2019

Page view(s)

252
checked on Sep 7, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.